🏛️ Verified NIH Record • Updated 2026-06-11
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (NCT04421963)
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca
🩺 Plain-English Summary (8th-Grade Level)
The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.
Who can join: Review the eligibility criteria below.
Location: Research Site — Boca Raton, Florida
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (107 Sites)
Showing the first 25 of 107 sites.
- Research Site — Boca Raton, Florida
- Research Site — Towson, Maryland
- Research Site — Detroit, Michigan
- Research Site — Minneapolis, Minnesota
- Research Site — Basking Ridge, New Jersey
- Research Site — Hackensack, New Jersey
- Research Site — New York, New York
- Research Site — The Bronx, New York
- Research Site — Philadelphia, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Willow Grove, Pennsylvania
- Research Site — Providence, Rhode Island
- Research Site — Germantown, Tennessee
- Research Site — Houston, Texas
- Research Site — Leuven,
- Research Site — Plovdiv,
- Research Site — Plovdiv,
- Research Site — Sofia,
- Research Site — Halifax, Nova Scotia
- Research Site — Kingston, Ontario
- Research Site — Mississauga, Ontario
- Research Site — Ottawa, Ontario
- Research Site — Toronto, Ontario
- Research Site — Toronto, Ontario
- Research Site — Montreal, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.